Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 47 min ago
PreprintCC BY-NC-NDmedRxiv

Unsupervised Phenotypic Stratification of 22q11.2 Deletion Syndrome for Improved Clinical Screening

  1. 1Universidade Estadual de Campinas

Abstract

Objective: 22q11.2 deletion syndrome (22q11DS) is the leading genetic cause of palatal anomalies, presenting a heterogeneous spectrum of clinical manifestations that complicates early diagnosis. No study has systematically investigated the co-occurrence of symptoms spanning cardiovascular, neuropsychiatric, craniofacial, immune, endocrine, renal, and familial domains within a single cohort using unsupervised learning methods for 22q11DS stratification. This study proposes a pipeline to identify subgroups and associated symptom patterns from binary clinical data, aiming to improve screening and referral for genetic testing. Design: Cross-sectional, retrospective study comparing three unsupervised clustering frameworks, K-medoids, DBSCAN, and Latent Class Analysis (LCA), followed by association rule mining applied to individuals with confirmed deletion. Setting: Brazilian Database of Craniofacial Anomalies (BBAC), a national clinical registry. Participants: A cohort of 297 individuals with suspected 22q11DS. Main Outcome Measures: Cluster separability (silhouette coefficient), characterization of phenotypic subgroups, and sensitivity/specificity of the current screening protocol stratified by subgroup. Results: LCA achieved the highest cluster separability (silhouette = 0.165), yielding four distinct subgroups: Cardiac-predominant (C0), Craniofacial-palatal (C1), Neurodevelopmental-psychiatric (C2), and Mild- craniofacial (C3). Cluster coherence was confirmed by medical specialists. Quantitative protocol assessment revealed adequate overall sensitivity, with markedly lower performance for C2 and C3, identifying profiles at higher risk of being missed by current screening criteria. Conclusions: These findings provide a data-driven basis for recalibrating symptom weights and referral thresholds, improving sensitivity for underperforming subgroups while reducing unnecessary referrals, optimizing the balance between diagnostic coverage and the financial burden of genetic testing.

Related

  1. Elucidating the pleiotropic effects of clpC deletion in Clostridioides difficile: proteomic and phenotypic insights
    Pierre-Alexandre Lacotte, Aurélie Lotoux, Kimberley Casado +6
    Microbial PathogenesisPeer-reviewedCC BY-NC 4.0Full textInfectious diseaseHAL
  2. Steroid Withdrawal Syndrome and Adrenal Insufficiency Following Unsupervised Steroid Use: A Case Report.
    Samit Kumar Gautam, Shardul Bhattarai, Aastha Dhakal +5
    Clinical case reportsPeer-reviewedCC BY-NC-NDFull textEndocrinology & metabolismEurope PMC
  3. Unsupervised phenotypic clustering, inferential characterization, and discriminant classification of elite flatwater canoeists: neuromuscular and anthropometric determinants
    Tania Álvarez-Yates, Óscar García-García, Alba Cuba-Dorado +3
    Frontiers in physiologyPeer-reviewedCC BYFull textSurgery & anaesthesiaEurope PMCPMCEurope PMC
  4. Negative Symptom Dimensions Link Cognitive Impairment to Global and Social Functioning in 22q11.2 Deletion Syndrome
    David A Parker, Marissa Chen, Elaine F Walker +8
    Schizophrenia researchPeer-reviewedLicence not statedFull textPsychiatry & mental healthPMC
  5. Phenotypic overlap between long QT syndrome type 1 and Brugada syndrome: Possible insights into monogenic and polygenic architecture.
    Kota Nakatsuji, Tsukasa Kamakura, Seiko Ohno +5
    HeartRhythm case reportsPeer-reviewedCC BY-NC-NDFull textCardiovascular medicineEurope PMC
BibTeX
@misc{soares2026unsupervised,
  title = {{Unsupervised Phenotypic Stratification of 22q11.2 Deletion Syndrome for Improved Clinical Screening}},
  author = {L. Azevedo Soares and D. Domeneghetti de Francisco and V. L. Gil-da-Silva-Lopes and G. Palermo Coelho and A. E. Antunes da Silva},
  howpublished = {medRxiv},
  year = {2026},
  month = oct,
  doi = {10.64898/2026.10.30.26366765},
  url = {https://www.medrxiv.org/content/10.64898/2026.10.30.26366765v1},
  note = {CC BY-NC-ND},
}
RIS
TY  - UNPB
TI  - Unsupervised Phenotypic Stratification of 22q11.2 Deletion Syndrome for Improved Clinical Screening
AU  - L. Azevedo Soares
AU  - D. Domeneghetti de Francisco
AU  - V. L. Gil-da-Silva-Lopes
AU  - G. Palermo Coelho
AU  - A. E. Antunes da Silva
PY  - 2026
DA  - 2026/10/30
PB  - medRxiv
DO  - 10.64898/2026.10.30.26366765
UR  - https://www.medrxiv.org/content/10.64898/2026.10.30.26366765v1
AB  - Objective: 22q11.2 deletion syndrome (22q11DS) is the leading genetic cause of palatal anomalies, presenting a heterogeneous spectrum of clinical manifestations that complicates early diagnosis. No study has systematically investigated the co-occurrence of symptoms spanning cardiovascular, neuropsychiatric, craniofacial, immune, endocrine, renal, and familial domains within a single cohort using unsupervised learning methods for 22q11DS stratification. This study proposes a pipeline to identify subgroups and associated symptom patterns from binary clinical data, aiming to improve screening and referral for genetic testing. Design: Cross-sectional, retrospective study comparing three unsupervised clustering frameworks, K-medoids, DBSCAN, and Latent Class Analysis (LCA), followed by association rule mining applied to individuals with confirmed deletion. Setting: Brazilian Database of Craniofacial Anomalies (BBAC), a national clinical registry. Participants: A cohort of 297 individuals with suspected 22q11DS. Main Outcome Measures: Cluster separability (silhouette coefficient), characterization of phenotypic subgroups, and sensitivity/specificity of the current screening protocol stratified by subgroup. Results: LCA achieved the highest cluster separability (silhouette = 0.165), yielding four distinct subgroups: Cardiac-predominant (C0), Craniofacial-palatal (C1), Neurodevelopmental-psychiatric (C2), and Mild- craniofacial (C3). Cluster coherence was confirmed by medical specialists. Quantitative protocol assessment revealed adequate overall sensitivity, with markedly lower performance for C2 and C3, identifying profiles at higher risk of being missed by current screening criteria. Conclusions: These findings provide a data-driven basis for recalibrating symptom weights and referral thresholds, improving sensitivity for underperforming subgroups while reducing unnecessary referrals, optimizing the balance between diagnostic coverage and the financial burden of genetic testing.
ER  -